Norman E. Lepor

MON-302 The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

Jorge Plutzky, Richard Joseph Auchus, JAN N. BASILE, Deepak L. Bhatt et autres

Abstract Disclosure: J. Plutzky: Altimmune, Amgen Inc, Boehringer Ingelheim, Corcept Therapeutics, New Amsterdam, Novo Nordisk, Toku Eyes, Esperion, Novartis Pharmaceuticals. R.J. Auchus: Neurocrine Biosciences/Neurocrine UK, LTD, Spruce Biosciences, Corcept Therapeutics, Crinetics Pharmaceuticals, Recordati Rare Diseases, Adrenas Therapeutics, Mineralys Therapeutics, Quest Diagnostics, Xeris …

us (code pays fourni par la source)

Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study

Gurleen Kaur, Robert S. Rosenson, Bariş Gencer, J. Antonio G. López et autres

us, ch, qa, ca (code pays fourni par la source)

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering

Michelle L. O’Donoghue, Robert S. Rosenson, J. Antonio G. López, Norman E. Lepor et autres

BACKGROUND: Olpasiran, a small interfering RNA (siRNA), blocks lipoprotein(a) (Lp(a)) production by preventing translation of apolipoprotein(a) mRNA. In phase 2, higher doses of olpasiran every 12 weeks (Q12W) reduced circulating Lp(a) by >95%. OBJECTIVES: This study sought to assess the timing of …

us, ca (code pays fourni par la source)

ASSOCIATION OF BASELINE LIPOPROTEIN(A) AND PERCENTAGE OF LIPOPROTEIN(A) LOWERING WITH OLPASIRAN

Michelle L. O’Donoghue, Robert S. Rosenson, Bariş Gencer, J. Antonio et autres

us (code pays fourni par la source)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

B. Alexander Yi, Debra Freedholm, Nancy Widener, Xiaohui Wang et autres

BACKGROUND: Factor XI (FXI) inhibition offers the promise of hemostasis-sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor …

us, gb (code pays fourni par la source)

Abstract 12706: Carotid Plaque Lipid Content is Reduced After 6 Months of Proprotein Convertase Subtilisin Kexin Type 9 Inhibition With Alirocumab: an Interim Analysis of a Serial Magnetic Resonance Imaging Study

Jie Sun, Norman E. Lepor, Gádor Cantón, Laurn Contreras et autres

Introduction: In the ODYSSEY OUTCOMES trial, proprotein convertase subtilisin kexin type 9 inhibition (PCSK9i) with alirocumab reduced recurrent major cardiovascular events by 15%, including 27% in...

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Christie Mitchell Ballantyne, Maciej Banach, G.B. John Mancini, Norman E. Lepor et autres

BACKGROUND AND AIMS: Patients with hyperlipidemia who are unable to tolerate optimal statin therapy are at increased cardiovascular risk due to ongoing elevations in low-density lipoprotein cholesterol (LDL-C). The objective of CLEAR Tranquility (NCT03001076) was to evaluate the efficacy and safety of …

us, pl, ca (code pays fourni par la source)

Phase 3 Evaluation of Bempedoic Acid Added to Ezetimibe in Patients with Elevated LDL-cholesterol Receiving No Greater Than Low Dose Statins: CLEAR Tranquility

Christie Mitchell Ballantyne, Maciej Banach, G.B. John Mancini, Norman E. Lepor et autres

us, pl, ca (code pays fourni par la source)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Erik S.G. Stroes, John R. Guyton, Norman E. Lepor, Fernando Civeira et autres

BACKGROUND: The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately …

nl, us, es, ca, au, fr (code pays fourni par la source)

An Update From the California Chapter of the American College of Cardiology Board of Directors

Norman E. Lepor

IMR Press is a leading publisher of open access peer-reviewed biomedical and life sciences journals. We aim to facilitate the dissemination of high-quality research in the area of biomedical science. With a long tradition and wide readership, IMR Press is dedicated to …

us (code pays fourni par la source)

Novel Agents for the Prevention and Management of Hyperkalemia

Peter Andrew McCullough, Maria Rosa Costanzo, Marc T. Silver, Bruce Spinowitz et autres

Hyperkalemia is defined as serum potassium concentrations elevated above the upper limit of normal (> 5.0 mEq/L). It has become more common in cardiovascular practice due to the growing population of patients with chronic kidney disease and the broad application of drugs …

us (code pays fourni par la source)

Correction to “The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia”

Norman E. Lepor, Laurn Contreras, Chirag Sureshchandra Desai, Dean J. Kereiakes

The support statement for Lepor NE et al, “The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia,” Rev Cardiovasc Med. 2014;15(4):290-309, was incorrectly attributed. This activity is supported by an educational grant from sanofi-aventis U.S. and Regeneron Pharmaceuticals. The …

us (code pays fourni par la source)